AstraZeneca Results Presentation Deck
Oligonucleotides
eplontersen (TTR ASO),
ATTRv-PN/CM - Phase III
AZD2693 (PNPLA3 ASO),
NASH - Phase llb
BioPharmaceuticals - novel platforms
Disruptive biology to access next-generation therapeutics
AZD7503 (HSD17B13 LICA),
NASH - Phase I
AZD2373 (APOL1 ASO),
CKD - Phase I
Advanced biologics
MEDI7352 (NGF/TNF),
pain - Phase II
CEO Opening Remarks
AZD8630 (ITSLP),
asthma - Phase I
Financial Results
Cell therapy
Procella -HF¹
THERAPEUTICS
Oncology
- CAR-Treg
Quellx (T1D and IBD)
BioPharmaceuticals
RNA therapies
mRNA
sa RNA
CRNA
Rare Disease
quide RNA
WILT
CEO Closing Remarks
PROLECE ITLENTE
Marching Hours
CASO
Gene therapy
Familial hyper-
cholesterolaemia (LDLR)
Duchenne musculo-
dystrophy (dystrophin)
1. Poch, C.M., Foo, K.S., De Angelis, M.T. et al. Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors. Nat Cell Biol 24, 659-671 (2022). https://doi.org/10.1038/s41556-022-00899-8. HF = heart
failure; Treg = T-regulator cell therapies; T1D = Type I Diabetes, IBD = Inflammatory Bowel Disease; TTR = transthyretin; ASO = antisense oligonucleotide; ATTR = transthyretin-mediated amyloid, PN = polyneuropathy, CM = cardiomyopathy;
23 PNPLA3 = patatin like phospholipase domain containing 3; NASH = non-alcoholic steatohepatitis; LICA = ligand-conjugated antisense; APOL1 = apolipoprotein L1; CKD = chronic kidney disease; LDLR = low density lipoprotein receptor; HTT=
huntingtin; mRNA = messenger ribonucleic acid; saRNA = small activating ribonucleic acid; CRNA = complementary ribonucleic acid; inhaled thymic stromal lymphopoietin; NGF/TNF = nerve growth factor/tumour necrosis factor-alpha.
Huntington's disease (HTT)View entire presentation